<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02222844</url>
  </required_header>
  <id_info>
    <org_study_id>CCR 4086</org_study_id>
    <nct_id>NCT02222844</nct_id>
  </id_info>
  <brief_title>Improving Radical Treatment Through MRI Evaluation of Pelvic Sigmoid Cancers</brief_title>
  <acronym>IMPRESS</acronym>
  <official_title>Improving Radical Treatment Through MRI Evaluation of Pelvic Sigmoid Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royal Marsden NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pelican Cancer Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Royal Marsden NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The IMPRESS trial aims to see whether the improved results can be achieved for patients with
      pelvic sigmoid cancers by having an MRI scan prior to surgery so that doctors can make the
      most appropriate treatment choice.

      Everyone who agrees to take part will be randomly allocated by one of the research team to
      either have standard treatment for sigmoid cancer, which involves CT-imaging of chest and
      abdomen / pelvis before surgery, or to undergo standard treatment, plus an additional MRI
      scan, before surgery. The additional MRI scan will be the only difference in approach between
      the two arms of the trial. After all imaging is obtained, patients from both arms will be
      discussed by the Multidisciplinary Team as usual. An amendment to this study in 2015 allowed
      for patients with sigmoid cancer who receive an MRI by local indication to be entered into
      the trial as observational patients, and a new primary endpoint added that compares the rates
      of high risk features identified between CT and MRI scans for all patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of the IMPRESS Trial will be to compare the proportion of patients
      undergoing any radical treatment in the two arms of the study. Another primary endpoint is to
      measure the difference in detection of high risk patients when comparing CT and MRI for all
      patients.

      Secondary outcomes will measure the proportion of patients who underwent neoadjuvant
      treatment, quality of surgery including free resection margins, perioperative morbidity and
      mortality, permanent defunctioning stoma rates, downstaging, quality of life at 1 year, 3
      years and 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To measure the difference in treatment stratification policy caused by the difference in findings between the CT and MRI.</measure>
    <time_frame>1 year post-surgery</time_frame>
    <description>Treatment is defined as (pre-operative) neoadjuvant treatment and/or extended surgery which would be offered for CT or MRI detected advanced T3 (&gt;T3b), EMVI positive, CRM involved sigmoid cancers. This objective will be assessed in both the observational and randomisation pathways.
Patients shown to have irresectable disease at baseline will be excluded from the primary endpoint analysis. Patients will be eligible for inclusion in the primary endpoint only if they have completed their planned baseline imaging (CT or CT+MRI) and were intended for curative treatment based on imaging results. Patients who subsequently withdrew from the trial for any reason before completion of curative treatment will be included in the analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To measure the proportion of patients who underwent neoadjuvant treatment in each arm.</measure>
    <time_frame>5 years after last recruit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the quality of surgery, including free resection margins, in each arm.</measure>
    <time_frame>5 years after last recruit</time_frame>
    <description>Quality of surgery will be assessed by the pathologist using a proforma sheet. Surgical resection margins, the amount of mesentery taken out and any peritoneal tears and length of vascular tie will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the perioperative morbidity and mortality in each arm.</measure>
    <time_frame>5 years after last recruit</time_frame>
    <description>Perioperative morbidity will include all adverse events within 30 days postoperatively. Perioperative mortality will include all deaths irrespective of cause within 30 days postoperatively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To measure and compare permanent defunctioning stoma rates in each arm.</measure>
    <time_frame>5 years after last recruit</time_frame>
    <description>Permanent defunctioning stomas is defined as stomas not reversed within 5 years postoperative follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To measure and compare radiological downstaging in each arm.</measure>
    <time_frame>5 years after last recruit.</time_frame>
    <description>Downstaging is defined as any improving of radiological TNM-stage on MRI after neoadjuvant treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare quality of life at 1 year, 3 years and 5 years in each arm.</measure>
    <time_frame>5 years after last recruit.</time_frame>
    <description>Using EORTC QLQ - CR29 quality of life form.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the proportion of patients having radical treatment between arms in the randomisation pathway</measure>
    <time_frame>5 years after last patient recruited</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">243</enrollment>
  <condition>Cancer</condition>
  <condition>Colorectal Neoplasms</condition>
  <condition>Colon, Sigmoid</condition>
  <condition>Magnetic Resonance Imaging</condition>
  <condition>General Surgery</condition>
  <arm_group>
    <arm_group_label>Preoperative CT scan</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>CT-imaging of chest and abdomen / pelvis before surgery (standard treatment)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Preoperative MRI scan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard treatment plus an additional MRI scan before surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observational</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Observational only</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Preoperative MRI scan</intervention_name>
    <description>Standard preoperative CT of abdomen, chest and pelvis plus interventional preoperative MRI scan.</description>
    <arm_group_label>Preoperative MRI scan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients with pelvic sigmoid colon (demonstrated on colonoscopy and biopsy) who
             are eligible for curative treatment (for the purposes of the IMPRESS study, the
             sigmoid tumour must be over 15cm from the anal verge)

        Exclusion Criteria:

        Less than 18 years old

          -  Unable to consent

          -  Consent witheld or withdrawn

          -  Unable to have an MRI (e.g. pacemaker, metal implant in major viscera, severe
             claustrophobia)

          -  Allergy or contraindication to Buscopan, small bowel contrast agent or gadolinium
             (e.g. glaucoma, small or large bowel obstruction, GFR &lt;30)

          -  A previous history of colorectal cancer

          -  Presence of irresectable distant metastases

          -  Severe co-morbidities that prevent the application of eventual chemo/radiotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gina Brown</last_name>
    <role>Principal Investigator</role>
    <affiliation>Consultant Radiologist and Professor in Cancer Imaging</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lisa Scerri</last_name>
    <phone>+442086613964</phone>
    <email>lisa.scerri@rmh.nhs.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Charlene Carvalho</last_name>
    <phone>+442089156495</phone>
    <email>charlene.carvalho@rmh.nhs.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hinchingbrooke Hospital</name>
      <address>
        <city>Huntingdon</city>
        <state>Cambridgeshire</state>
        <zip>PE29 6NT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Mitchell</last_name>
      <email>davidmitchell4@nhs.net</email>
    </contact>
    <contact_backup>
      <last_name>Susan Donnelly</last_name>
      <email>susan.donnelly1@nhs.net</email>
    </contact_backup>
    <investigator>
      <last_name>David Mitchell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leighton Hospital</name>
      <address>
        <city>Crewe</city>
        <state>Cheshire</state>
        <zip>CW1 4QJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chris Hough</last_name>
      <email>Chris.Hough@mcht.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Vanessa Adamson</last_name>
      <email>Vanessa.Adamson@mcht.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Braun</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of North Tees</name>
      <address>
        <city>Stockton-on-Tees</city>
        <state>County Durham</state>
        <zip>TS19 8PE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helen Wilson</last_name>
      <email>Helen.Wilson2@nth.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Anil Agarwal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Croydon University Hospital</name>
      <address>
        <city>Thornton Heath</city>
        <state>Croydon</state>
        <zip>CR7 7YE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Muti Abulafi</last_name>
      <email>muti.abulafi@nhs.net</email>
    </contact>
    <contact_backup>
      <last_name>Ibiyemi Sadare</last_name>
      <email>ibiyemi.sadare@nhs.net</email>
    </contact_backup>
    <investigator>
      <last_name>Muti Abulafi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chesterfield Royal</name>
      <address>
        <city>Chesterfield</city>
        <state>Derbyshire</state>
        <zip>SS4 5BL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lesley Stevenson</last_name>
      <email>lesley.stevenson@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Harjeet Singh Narula</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Alexandra Hospital</name>
      <address>
        <city>Portsmouth</city>
        <state>Hampshire</state>
        <zip>PO6 3LY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony Higginson</last_name>
      <email>antony.higginson@porthosp.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Nicola Gibbons</last_name>
      <email>nicola.gibbons@porthosp.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Anthony Higginson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Mark's Hospital</name>
      <address>
        <city>Middlesex</city>
        <state>Harrow</state>
        <zip>HA1 3UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony Antoniou</last_name>
      <email>a.antoniou1@nhs.net</email>
    </contact>
    <contact_backup>
      <last_name>Pooja Datt</last_name>
      <email>pooja.datt@nhs.net</email>
    </contact_backup>
    <investigator>
      <last_name>Anthony Antoniou</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maidstone Hospital</name>
      <address>
        <city>Maidstone</city>
        <state>Kent</state>
        <zip>ME16 9QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paulette Basham</last_name>
      <email>paulette.basham@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Sukanya Ghosh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth the Queen Mother Hospital</name>
      <address>
        <city>Margate</city>
        <state>Kent</state>
        <zip>CT9 4AN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Turney</last_name>
      <email>sharon.turney@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Jess Evans</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Manchester General Hospital</name>
      <address>
        <city>Crumpsall</city>
        <state>Manchester</state>
        <zip>M8 5RB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salim Kurrimboccus</last_name>
      <email>Salim.Kurrimboccus@pat.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Joanne Allsop</last_name>
      <email>Joanne.Allsop@pat.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Salim Kurrimbossus</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of South Manchester &amp; Manchester Royal Infirmary</name>
      <address>
        <city>Wythenshawe</city>
        <state>Manchester</state>
        <zip>M23 9LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Duff</last_name>
      <email>Sarah.Duff@UHSM.NHS.UK</email>
    </contact>
    <contact_backup>
      <last_name>Lindsay Piper</last_name>
      <email>Lindsay.Piper@UHSM.NHS.UK</email>
    </contact_backup>
    <investigator>
      <last_name>Sarah Duff</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Harrogate District Hospital</name>
      <address>
        <city>Harrogate</city>
        <state>North Yorkshire</state>
        <zip>HG2 7SX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Leinhardt</last_name>
    </contact>
    <contact_backup>
      <last_name>Lisa Jones</last_name>
      <email>Lisa.Jones@hdft.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>David Leinhardt</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Musgrove Park Hospital</name>
      <address>
        <city>Taunton</city>
        <state>Somerset</state>
        <zip>TA1 5DA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Ashcroft</last_name>
      <email>Jan.ashcroft@tst.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Erica Beaumont</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yeovil District Hospital</name>
      <address>
        <city>Yeovil</city>
        <state>Somerset</state>
        <zip>BA21 4AT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital</name>
      <address>
        <city>Sutton</city>
        <state>Surrey</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Scerri</last_name>
      <email>lisa.scerri@nhs.net</email>
    </contact>
    <contact_backup>
      <last_name>Charlene Carvalho</last_name>
      <phone>442089156067</phone>
      <email>charlene.carvahlo@rmh.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Gina Brown</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Salisbury District Hospital</name>
      <address>
        <city>Salisbury</city>
        <state>Whiltshire</state>
        <zip>SP2 8BJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Graham Branagan</last_name>
      <email>Graham.Branagan@salisbury.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Ruth Casey</last_name>
      <email>Ruth.Casey@salisbury.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Graham Branagan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 20, 2014</study_first_submitted>
  <study_first_submitted_qc>August 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 21, 2014</study_first_posted>
  <last_update_submitted>February 2, 2018</last_update_submitted>
  <last_update_submitted_qc>February 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>Colorectal Neoplasms</keyword>
  <keyword>Colon, Sigmoid</keyword>
  <keyword>Magnetic Resonance Imaging</keyword>
  <keyword>General Surgery</keyword>
  <keyword>Postoperative Complications</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Sigmoid Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

